Chemotherapy was administered at home to a cancer patient in the Florida Panhandle on January 9, 2026. There is no waiting area. A four-hour drive to a treatment facility is not necessary. No making plans for someone to accompany them while a bag leaked into their arm in a hospital hallway. A nurse approached them. The same course of action was taken. The place was completely different. By all standards, it was a minor issue. Additionally, it was the first delivery under a program that has the potential to transform cancer care for rural patients throughout a whole state.
The Mayo Clinic in Florida is leading the Cancer CARE (Connected Access and Remote Expertise) Beyond WallsTM pilot clinical trial, which is supported by the Florida Cancer Innovation Fund. The program, which was created especially for patients in the Florida Panhandle who have the unique challenge of living hours away from the closest specialized cancer center, received more than $1.8 million from the fund. On December 18, 2025, the trial began. Four days later, the first patient gave their consent. In-home therapy was being provided by January 9. The time between announcement and actual patient care was remarkably short for a state-funded program.
That speed is deliberate. Instead of the kind of multi-year research cycles that can take ten years to reach a patient’s bedside, the Florida Cancer Innovation Fund, which was established through the Casey DeSantis Cancer Research Program and has been funded with a total of $140 million since its inception, is built around one-year projects specifically designed to produce immediate, measurable results. A specific diagnosis of what has gone wrong with healthcare innovation is reflected in the fund’s structure: the discrepancy between what research can accomplish and what patients in rural areas actually receive is not primarily a scientific one. There is a gap in the systems. There are answers. It takes intentional, financially supported, and accountable work to get them to the right people.
The Mayo Clinic program expands upon something that has been demonstrated in a controlled environment. As part of its Advanced Care at Home capabilities, which replicate hospital-level care in a patient’s living room, Mayo Clinic in Florida has administered more than 1,000 in-home chemotherapy, immunotherapy, and hormone therapy treatments since April 2023. With the Panhandle expansion, that infrastructure is extended into areas with the greatest need. Dr. Roxana Dronca, who oversees the study and is the site director of the Mayo Clinic Comprehensive Cancer Center in Florida, outlined the program’s goals in simple terms: eliminate obstacles, provide quality, and lessen the burden of travel.
A few hundred miles to the south, the University of South Florida and Tampa General Hospital Cancer Institute are addressing a different set of obstacles by implementing an AI-driven platform to combat cervical cancer in rural areas. More than half of cervical cancer cases in some Florida counties are diagnosed at an advanced stage, which is a painfully clear indication of the problem they are trying to solve. Not because there was no way to detect the cancer. Because in rural primary care settings, the systems for detecting it—screening, follow-up, and referral to specialty care—were either disjointed or nonexistent. An AI navigation platform at four high-volume rural clinics will be funded by the nearly $2 million Innovation Fund award.
This platform will identify patients who are past due for screening, facilitate HPV self-testing, and ensure that abnormal results trigger timely follow-up rather than disappearing into the kind of administrative gap that, in a rural county, can mean a six-month delay and a significantly worse prognosis. The project lead, Dr. Matthew Anderson, stated bluntly, “Too often rural communities lack the systems needed to deliver those tools.” The technology is already in place. There hasn’t been any coordination.
| Topic | Florida Cancer Innovation Fund — Rural Cancer Care Transformation |
|---|---|
| Parent Program | Casey DeSantis Cancer Research Program (Florida Statutes § 381.915) |
| Total Fund Size | $140 million received since inception; $60 million announced September 2025 |
| Key Grant 1 | Mayo Clinic in Florida — “Cancer CARE Beyond Walls™” — $1.8 million+ |
| Key Grant 2 | Florida Cancer Specialists & Research Institute (FCS) — $3.3 million (two grants) |
| Key Grant 3 | USF Health / Tampa General Hospital Cancer Institute — nearly $2 million |
| First Patient Treated | January 9, 2026 — in-home chemotherapy, Florida Panhandle |
| Clinical Trial Launch | December 18, 2025 — Panhandle pilot; 27 patients planned |
| USF/TGH Initiative | AI-driven cervical cancer screening across 4 rural primary care clinics; 662,000+ rural Floridians targeted |
| FCS Remote Monitoring | TempShield™ wearable thermometer (AION Biosystems, FDA-cleared) detects infections 2-3 days before symptoms |
| Clinical Trial Disparity | 4.1% community oncology enrollment vs. 21.6% at academic cancer centers |
| Infection Burden | Infections drive 60% of cancer-related deaths and 15% of unplanned hospitalizations |
| Reference Links | Governor’s Office – First Lady Casey DeSantis Announces First Patient Treated / USF Health – USF Health, TGH to Use State Innovation Funds for Rural Cancer Care |

Then there is the work being done by Florida Cancer Specialists & Research Institute, which was awarded two grants totaling more than $3.3 million. The FDA-approved wearable device TempShieldTM, created by AION Biosystems, is being used in one project to scale a remote temperature monitoring program. It can identify fever-precursor signs two to three days before a patient’s body signals any obvious symptoms. That window of two to three days is very important. 60% of cancer-related deaths and 15% of unscheduled hospital stays among cancer patients are caused by infections. Early detection does more than just cut down on ER visits. Lives are saved by it. Closing the clinical trial access gap, which has existed for decades without much apparent urgency from the institutions that benefit from it, is the main goal of the second FCS project. Compared to 21.6% at larger academic cancer centers, only 4.1% of patients at community oncology programs ever sign up for clinical trials.
The rural research initiative’s director, Dr. Bradley Monk, was straightforward about the implications of that figure: patients in rural areas with poorer outcomes and fewer resources are less likely to receive the treatments that are most likely to benefit them.
When considering these initiatives collectively, it seems as though Florida has reached a certain level of pragmatism regarding rural health equity. Real funded programs that treat real patients in real homes, not the idealistic language of strategic plans. It’s not too late yet. As of the initial announcement, four patients had been enrolled in the Panhandle trial, which aims to consent 27 patients. Rural clinics are just starting to use the AI cervical screening platform. The program for remote monitoring is expanding from a successful pilot. This is all unfinished. Everything is operating.
